KMTS: Revenue up 60% year-over-year, gross margin at 56.5%, FY27 guidance raised to $141M

Revenue surged 60% year-over-year to $31.0 million with gross margin expanding to 56.5%. Net loss widened to $44.1 million, while FY27 revenue guidance was raised to $141 million, reflecting 48% projected growth.Original document: Kestra Medical Technologies, Ltd. [KMTS] SEC 8-K Current Report — Se…